- Statin therapy is independently associated with a reduced risk for long-term all-cause mortality in patients presenting with ventricular tachyarrhythmias on admission.
Why this matters
- At present, limited data exist regarding the outcomes of patients with statin therapy presenting with ventricular tachyarrhythmias.
- This retrospective study included 424 propensity-matched patients admitted with ventricular tachyarrhythmias.
- Impact of statin therapy on survival was evaluated.
- Primary endpoint: all-cause death at 3 years.
- Funding: None.
- Majority of patients presented with ventricular tachycardia (VT) vs ventricular fibrillation (VF) with equally distributed rates in statin and non-statin groups (VT: 71% vs 68%; VF: 29% vs 32%).
- At long-term follow-up (median, 3 years), patients on statin therapy had significantly better survival vs patients on non-statin (mortality rates, 16% vs 33%; log rank P=.001; HR, 0.438; 95% CI, 0.290-0.663; P=.001).
- The prognostic benefit of statin therapy was irrespective of presence of VT (mortality rates, 15% vs 33%; log rank P=.001; HR, 0.439; 95% CI, 0.267-0.723; P=.001) or VF (mortality rates, 16% vs 34%; log rank P=.028; HR, 0.445; 95% CI, 0.212-0.935; P=.032).
- The prognostic benefit of statin therapy was evident when stratifying according to left ventricular ejection fraction >35%, presence of an activated implantable cardioverter defibrillator (ICD), cardiogenic shock or cardiopulmonary resuscitation.
- Retrospective design.